Enveric Biosciences narrows net loss, advances lead drug candidate
Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the third quarter of 2024 and provided a corporate update yesterday. Enveric said it made “important progress” in the development of EB-003, its lead neuroplastogenic molecule designed to treat depression, anxiety and addiction disorders without causing the hallucinogenic effects common to DMT and related analogs. According […]
